pages:
-
Advancing a Formal Multidisciplinary Surgical Simulation Curriculum through High Fidelity Laparoscopic Simulation
-
Advancing B.Sc. in Engineering Students in Hybrid-Electric and Electric Vehicles
-
Advancing Health Equity
-
Advancing Health Equity in Jefferson County II
-
Advancing Health Equity in Jefferson County, AL
-
Advancing PINK1 KO Rat Animal Models of PD
-
Advancing PINK1 KO Rat Animal Models of PD
-
Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2
-
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
-
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
-
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
-
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
-
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
-
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
-
ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
-
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
-
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
-
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
-
Aerobic Training During or After Adjuvant Therapy: A Randomized Trial
-
Affect of Oxygen Tension on Glioma Stem Cells
-
African American Collaborative Obesity Research Network
-
African American Lesbian Families, Sororities and Fraternities and Their Role in the Promotion of Sexual Health and Prevention of Sexually Transmitted Infections in LGBT Communities
-
African Descent and Glaucoma Evaluation (ADAGES)
-
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma Progression
-
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression
-
Age of Blood in Children in Pediatric Intensive Care Unit
-
Age of Blood in Children in Pediatric Intensive Care Units
-
Age of Blood in Children in Pediatric Intensive Care Units (ABC-PICU)
pages:
